ANTH Dims On BRIGHT-SC Data, CYAD Fails To Chart, LLY Gets FDA Panel Nod

Shares of Celyad SA (CYAD) plunged 33% on Tuesday after the company's phase III trial evaluating C-Cure for the treatment of heart failure, dubbed CHART-1, failed to reach the primary endpoint.

from RTT - Biotech http://ift.tt/292YSY1
via IFTTT